Title(s): CTSU E1609. A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-risk Melanoma
Investigator(s):
Esther Rehmus, MD
Contact
Information:
McDowell Cancer Research at 330-344-6348
